TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01291056
Drug: Clomiphene
Normalized name: Clomiphene
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
Study: NCT00605813
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.~Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.~Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration.
Study: NCT01506882
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: * Active Substance: Levetiracetam~* Pharmaceutical Form: Film-coated tablet~* Concentration: LEV 250 mg, LEV 500 mg~* Frequency: Twice daily~* Route of Administration: Oral use
Study: NCT02207790
Drug: E2609
Normalized name: Elenbecestat
DrugBank: Elenbecestat (DB15391)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00212732
Drug: ONO-8025 (KRP-197)
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02567799
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During the Concurrent Therapy period, area under the curve (AUC) = 2mg\* min/mL will be administered by intravenous drip weekly during weeks 1-6.~During the Consolidation Therapy period, carboplatin AUC = 6mg\*min/mL will be administered by intravenous drip two times, 21 days apart.
Study: NCT02369081
Drug: Bisoprolol
Normalized name: Bisoprolol
DrugBank: Bisoprolol (DB00612)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
Study: NCT04309656
Drug: Pretomanid
Normalized name: Pretomanid
DrugBank: Pretomanid (DB05154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Treatment A (reference) = 200 mg given as a single 200 mg tablet (using the immediate release formulation), orally administered.~2. Treatment B (test) = 200 mg given as four 50-mg tablets (using the dispersible pediatric formulation), orally administered.~3. Treatment C (test) = single 50-mg dispersible tablet, orally administered.~4. Treatment D (test) = single 10-mg dispersible tablet, orally administered.
Study: NCT03772847
Drug: ginkgolide
Normalized name: GINKGOLIDE B
DrugBank: Ginkgolide A (DB06743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ginkgolide plus alteplase
Study: NCT00087711
Drug: pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2, IV q 21 days x 6 cycles
Study: NCT00087711
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles
Study: NCT00087711
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2, IV, q 21 days x 6 cycles
Study: NCT00873509
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
Study: NCT00873509
Drug: Buspirone
Normalized name: Buspirone
DrugBank: Buspirone (DB00490)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
Study: NCT02369081
Drug: Doxazosin
Normalized name: Doxazosin
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
Study: NCT02411292
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
Study: NCT02262806
Drug: Metreleptin
Normalized name: Metreleptin
DrugBank: Metreleptin (DB09046)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with partial lipodystrophy.
Study: NCT00465972
Drug: Doxepin
Normalized name: Doxepin
DrugBank: Doxepin (DB01142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
Study: NCT00465972
Drug: Temazepam
Normalized name: Temazepam
DrugBank: Temazepam (DB00231)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Temazepam capsule 15 mg po nightly x duration of study
Study: NCT02784821
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Babies that are assigned to antibiotics receive therapy based on the clinical team's discretion.
Study: NCT01139450
Drug: Tacrolimus Ointment 0.03%
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference product for 0417 test product. Apply twice daily for 4 weeks
Study: NCT01517009
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
Study: NCT01517009
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg/m2, one gift every three weeks, in total 4 gift
Study: NCT02149927
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01277523
Drug: tiotropium high dose
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 actuations once daily
Study: NCT01277523
Drug: tiotropium low dose
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 actuations once daily
Study: NCT04608500
Drug: Vehicle foam
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form description: Foam containing minocycline vehicle foam. Once daily application of a sufficient amount of foam to cover the entire face. Estimated maximum is 0.5 g of drug product containing 0.0 mg (vehicle) of minocycline. Participants will apply a small amount of the drug as a thin layer over all areas of the face. Participants should apply the drug at approximately the same time each day, about 1 hour before bedtime.
Study: NCT02695745
Drug: V116517 aqueous suspension
Normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
DrugBank: V116517 (DB16060)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
Study: NCT02695745
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1% administered topically
Study: NCT03666923
Drug: THR-687 dose level 1
Normalized name: Thr
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single intravitreal injection of THR-687 dose level 1
Study: NCT03666923
Drug: THR-687 dose level 2
Normalized name: Thr
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single intravitreal injection of THR-687 dose level 2
Study: NCT03666923
Drug: THR-687 dose level 3
Normalized name: Thr
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single intravitreal injection of THR-687 dose level 3
Study: NCT00919776
Drug: ciclosporin
Normalized name: Ciclosporin
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
Study: NCT01899638
Drug: UMEC 125 mcg
Normalized name: Umecta
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LAMA mono in high dose
Study: NCT02670655
Drug: lidocaine/prilocaine (5%) application
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
Study: NCT01157507
Drug: Intravesical injection of Botulinum A Toxin
Normalized name: botulinum toxin type A Injection
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: One treatment, 100 U vials diluted in 10 ml normal saline
Study: NCT01170182
Drug: Omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole Delayed Release Capsules 40 mg
Study: NCT00817895
Drug: sustained released 5-FU and sustained released cisplatin
Normalized name: 5-FU
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
Study: NCT00817895
Drug: sustained released 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
Study: NCT00174915
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 80 mg, orally, once daily for up to 28 weeks.
Study: NCT00174915
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 120 mg, orally, once daily for up to 28 weeks.
Study: NCT00174915
Drug: Febuxostat
Normalized name: Febuxostat
DrugBank: Febuxostat (DB04854)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Febuxostat 240 mg, orally, once daily for up to 28 weeks.
Study: NCT00174915
Drug: Allopurinol
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine \>1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
Study: NCT01837992
Drug: Primaquine
Normalized name: Primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01837992
Drug: delayed primaquine
DrugBank: Primaquine (DB01087)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00130039
Drug: clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
Study: NCT00130039
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
Study: NCT00642707
Drug: PRO 140 (humanized monoclonal antibody to CCR5)
Normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00882193
Drug: Betaine
Normalized name: betaine
DrugBank: Betaine (DB06756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betaine 20 gm/day in 2 divided doses for 48 weeks
Study: NCT00882193
Drug: Peginterferon alpha 2a
Normalized name: peginterferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
Study: NCT00882193
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight \< or \> 75mg in 2 divided doses
Study: NCT00293696
Drug: bicalutamide (Casodex), goserelin (Zoladex)
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00017303
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00017303
Drug: oglufanide disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Oglufanide (DB05779)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00017303
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00112502
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg/m\^2 orally twice a day (total daily dose = 80 mg/m\^2) days 1-21 of a 28 day cycle.
Study: NCT00343564
Drug: SB-743921
Normalized name: SB-743921
DrugBank: SB-743921 (DB05546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
Study: NCT00343564
Drug: SB-743921
Normalized name: SB-743921
DrugBank: SB-743921 (DB05546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
Study: NCT02151786
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole intravenous 30 mg
Study: NCT00112502
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg/m2 orally daily, 7 days on treatment, 7 days off.
Study: NCT02752490
Drug: Liberal use of maternal oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
Study: NCT02752490
Drug: Indicated use of maternal oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
Study: NCT01102491
Drug: Ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
Study: NCT00112502
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
Study: NCT02385266
Drug: D-Cycloserine
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
Study: NCT02385266
Drug: Placebo (for D-cycloserine)
Normalized name: D-(+)-cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactose filled capsules to mimic DCS 200mg capsules
Study: NCT01280292
Drug: Eltroxin
Normalized name: Eltroxin
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eltroxin dosage titration according to free T4 measurement every 3 months
Study: NCT03161431
Drug: SX-682
Normalized name: SX-682
DrugBank: SX-682 (DB19210)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
Study: NCT01367574
Drug: SC MNTX
Normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose 1
Study: NCT01367574
Drug: SC MNTX
Normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose 2
Study: NCT01367574
Drug: SC MNTX
Normalized name: MNTX
DrugBank: Methylnaltrexone (DB06800)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose 3
Study: NCT01941927
Drug: Trametinib (GSK1120212)
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib is a highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity.
Study: NCT02648009
Drug: Gadolinium
Normalized name: gadolinium
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI with Gadolinium
Study: NCT04345692
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet administered by hospital staff or if discharged before day 5 - self administered oral tablet
Study: NCT00834210
Drug: Dapsone
Normalized name: Dapsone
DrugBank: Dapsone (DB00250)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
Study: NCT00834210
Drug: Tazarotene
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
Study: NCT02254044
Drug: bivatuzumab mertansine
Normalized name: Bivatuzumab
DrugBank: Bivatuzumab (DB06550)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04029428
Drug: 90Y-DOTATATE
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total activity of 90Y DOTATATE, 4x3.7GBq (14.8 GBq). Single session of i.v. infusion of 90Y DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 90Y DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
Study: NCT04029428
Drug: (177Lu-DOTAOTyr3)Octreotate
Normalized name: 177Lu-DOTA-octreotate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total activity of 177Lu DOTATATE, 4x5.55GBq (22.2 GBq). Single session of i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
Study: NCT04029428
Drug: 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)
Normalized name: 177Lu-dotatate
DrugBank: Dotatate (DB14554)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total activity of 90Y DOTATATE and 177Lu DOTATATE, 4x3.7GBq (14.8 GBq 50% each 90Y and 177Lu). Single session of i.v. infusion of 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
Study: NCT00993863
Drug: ADL5859 30 mg
Normalized name: ADL5859
DrugBank: ADL5859 (DB05050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT00993863
Drug: ADL5859 100 mg
Normalized name: ADL5859
DrugBank: ADL5859 (DB05050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT00993863
Drug: ADL5859 200 mg
Normalized name: ADL5859
DrugBank: ADL5859 (DB05050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose
Study: NCT00647244
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir disoproxil 245 mg oral tablet once daily
Study: NCT00647244
Drug: Abacavir
Normalized name: Abacavir
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abacavir 300 mg oral tablet twice daily
Study: NCT00396786
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
Study: NCT00396786
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
Study: NCT00396786
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
Study: NCT00396786
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
Study: NCT00396786
Drug: Rivaroxaban (Xarelto, BAY59-7939)
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
Study: NCT00396786
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
Study: NCT00269750
Drug: OROS® oxybutynin or Ditropan®
DrugBank: Oxybutynin (DB01062)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01510990
Drug: Gefitinib
Normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gefitinib 250mg/day daily
Study: NCT03265145
Drug: Stiolto Respimat
Normalized name: Stiolto Respimat 28 ACT
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration - 12 months
Study: NCT03265145
Drug: ICS (Inhaled Corticosteroid) (Triple therapy)
Normalized name: Camphor Ice Topical Product
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duration - 12 months
Study: NCT03265145
Drug: LABA (Long-Acting Beta Agonist) (Triple therapy)
Normalized name: Labafenogene marselecobac
DrugBank: Labafenogene marselecobac (DB17618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration - 12 months
Study: NCT03265145
Drug: LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
Normalized name: Lama palagi oil
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duration - 12 months